OpenAlex
PricingAboutJobs
Log inGet started
Work

Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy

HTML

Year: 2007
Type: article
Study design: Clinical Trial
Source: Annals of the Rheumatic Diseases
DOI: 10.1136/ard.2007.074773
Authors: M C Genovese, M Schiff, M Luggen, J-C Becker, R Aranda, J Teng, T Li, N Schmidely, M Le Bars, M Dougados
Institutions: Stanford University, Denver Arthritis Clinic, University of Cincinnati Medical Center, Bristol-Myers Squibb (United States), Bristol-Myers Squibb (France), Hôpital Cochin, Université Paris Descartes
Language: English

Topic: Rheumatoid Arthritis Research and Therapies
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Keywords: abatacept, rheumatoid arthritis, long-term extension study, treatment safety, disease activity, remission, HAQ-DI, fatigue, quality of life, serious adverse events, disease-modifying antirheumatic drugs, ACR response criteria, DAS28-CRP, sleep disorders
SDG: Good health and well-being

Open Access status: closed

Funder: National Center for Research Resources
Award: General Clinical Research Center
OpenAlex ID: W2115018403
FWCI: 17.41
Cites: 21
Cited by: 293
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms